Search results for: life sciences & biotech

Life Sciences & Biotech

At GJE our specialist and highly experienced biotech patent attorneys have a deep understanding of the commercial realities of the sector. We appreciate the strategic value of IP to a biotech company�...

GJE announces alliance with Wächtershäuser & Hartz

GJE is pleased to announce that the firm has formed an alliance with the German patent and trade mark firm Wächtershäuser & Hartz (W&H)...

Biotech Buddies London | 14.03.2024

Thursday 14 March 2024 I 6:00 pm (London UK – GMT) GJE look forward to hosting the next Biotech Buddies networking event at our office in Broadgate Tower. Several members of our chemistry and life s...

Imago BioSciences Announces $40M Series B Financing Led by Omega Funds

On 21 March, Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, announced a $40 million Series B financing led by Omega Funds, a GJE...

Key considerations when patenting microbiome inventions in Europe

In the latest article in our series, we outline the key considerations for innovators and applicants when patenting microbiome-related technologies in Europe....

Key considerations when patenting PROTACs in Europe

In this article, we outline the key considerations for innovators and applicants when patenting PROTACs in Europe....

Key considerations when patenting CRISPR-based therapeutics in Europe

In this article, we set out the key aspects for innovators and applicants to consider when patenting gene editors in Europe....

Innovation in the agri-tech space: How hard does the “essentially biological process” exclusion bite?

We examine why it is crucial for agri-tech companies to have awareness of the ''essentially biological process'' exclusion and when alternatives to patent protection should be considered....

Key considerations when patenting gene editors in Europe

We set out the key things for innovators and applicants to consider when patenting gene editors in Europe....

Key considerations when patenting chimeric antigen receptor technologies in Europe

We explore the therapeutic indications addressed by Chimeric Antigen Receptors (CARs) and CAR T-cell therapy and consider patent protection at the EPO...